No certified diagnostic methods are documented in this packet beyond the histopathologic description provided in the disease definition: polygonal, deeply eosinophilic tumor cells embedded in a fibrous lamellar stroma, arising in non-cirrhotic livers.

No FL-HCC-specific approved therapies are certified in this packet. Atezolizumab combined with bevacizumab (Tecentriq/Avastin) and pembrolizumab (Keytruda) hold FDA approvals for hepatocellular carcinoma broadly, not specifically for fibrolamellar HCC. A compound (C66H100N6O27) holds an orphan drug designation for HCC treatment. Active clinical trials are investigating multiple agents in FL-HCC and pediatric HCC populations.

Natural history data are not certified in this packet. The disease definition states that prognosis is comparable to classical HCC in non-cirrhotic livers and more favorable than HCC arising in cirrhotic livers.

ClinicalTrials.gov records 10 active or ongoing studies, including a Phase 3 study in children and young adults (NCT03533582), Phase 1 peptide vaccine trials targeting the DNAJB1-PRKACA fusion kinase (NCT04248569; NCT06789198), a Phase 1 safety and efficacy study of combination systemic therapy (NCT05468359), and a Phase 1 glutamine antagonist trial (NCT06027086). The research landscape encompasses 81 classified publications, predominantly case reports (24) and reviews (7), with documented biomarker and gene therapy research.